Enfuvirtide + Tenofovir-Emtricitabine

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Leukoencephalopathy, Progressive Multifocal

Conditions

Leukoencephalopathy, Progressive Multifocal, HIV Infections

Trial Timeline

Apr 1, 2005 → Dec 1, 2007

NCT ID

NCT00120367

About Enfuvirtide + Tenofovir-Emtricitabine

Enfuvirtide + Tenofovir-Emtricitabine is a phase 2 stage product being developed by Roche for Leukoencephalopathy, Progressive Multifocal. The current trial status is completed. This product is registered under clinical trial identifier NCT00120367. Target conditions include Leukoencephalopathy, Progressive Multifocal, HIV Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00120367	Phase 2	Completed	Apr 1, 2005	Dec 1, 2007	Leukoencephalopathy, Progressive Multifocal

Competing Products

2 competing products in Leukoencephalopathy, Progressive Multifocal

See all competitors

Product	Company	Stage	Hype Score
mefloquine	Biogen	Phase 1/2	21
Tysabri	Biogen	Pre-clinical	23